Phase III study of S-1 plus intravenous and intraperitoneal paclitaxel versus S-1 plus cisplatin for gastric cancer with peritoneal metastasis
Phase 3
- Conditions
- gastric cancer with peritoneal metastasis
- Registration Number
- JPRN-UMIN000005930
- Lead Sponsor
- The University of Tokyo Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 180
Inclusion Criteria
Not provided
Exclusion Criteria
1) Metastasis to distant organ sites other than the ovary 2) Contraindication to S-1, cisplatin or paclitaxel 3) Apparent infection or inflammation 4) Severe heart disease 5) Severe complication 6) Massive ascites requiring drainage for palliation 7) Gastrointestinal tract bleeding requiring blood transfusion 8) Severe diarrhea (more than 4 times a day and/or watery) 9) Psychiatric disorder requiring medication 10) Other active concomitant malignancies 11) Pregnancy, breast feeding or intention to become pregnant 12) Judged inappropriate for this trial for other reasons
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method